Yao Hairong, Chen Hao, Chen Jianguo, Zhu Jian, Zhang Yonghui
Qidong Liver Cancer Institute, Qidong People's Hospital, 226200 Jiangsu, China.
Zhonghua Gan Zang Bing Za Zhi. 2014 Dec;22(12):921-5. doi: 10.3760/cma.j.issn.1007-3418.2014.12.009.
To determine the survival rates of liver cancer in Qidong during the years 1972-2011, according to the data from a population-based cancer registry, in order to assess the long-term trends for prognosis of this cancer type.
The deadline of the last follow-up for survival status of the 28, 398 registered cases was April of 2012. Cumulative observed survival (OS) and relative survival (RS) rates were calculated using Hakulinen's method performed by the SURV3.01 software developed by the Finnish Cancer Registry.
The 1-, 3-, 5-, 10-and 15-year OS rates were 15.18%, 6.23%, 4.26%, 2.79% and 2.39%, respectively; the 1-, 3-, 5-, 10-and 15-year RS rates were 15.47%, 6.60%, 4.69%, 3.41% and 3.29%, respectively. For males, these OS rates were 14.95%, 6.05%, 4.06%, 2.67% and 2.26%, and these RS rates were 15.23%, 6.41%, 4.47%, 3.26% and 3.12%, respectively. For females, these OS rates were 15.89%, 6.79%, 4.87%, 3.17% and 2.80%, and these RS rates were 16.20%, 7.20%, 5.37%, 3.87% and 3.82%, respectively. No statistical differences were found between the male and female groups (P>0.05). The 5-year RS rates for age groups 15-34, 35-44, 45-54, 55-64, 65-74 and 75+ years-old were 4.42%, 4.29%, 4.96%, 4.67%, 4.67% and 6.35%, and the 10-year RS rates were 3.17%, 2.98%, 3.44%, 3.47%, 3.75% and 11.27%, respectively. Remarkable improvement was seen for the 1-, 3-, 5-, 10-and 15-year OS rates in this setting since the 1980s.
The survival outcome from Qidong registered cases with liver cancer has shown gradual progress over the past four decades. Early detection and improvement of therapies may be responsible for the improved prognosis of liver cancer. While the disparity gap of survival between this area and developed countries is narrowing, there is still a need for improving the survival in Qidong.
根据基于人群的癌症登记数据，确定启东1972年至2011年期间肝癌的生存率，以评估这种癌症类型预后的长期趋势。
28398例登记病例生存状态的最后随访截止日期为2012年4月。使用芬兰癌症登记处开发的SURV3.01软件通过Hakulinen方法计算累积观察生存率（OS）和相对生存率（RS）。
1年、3年、5年、10年和15年的OS率分别为15.18%、6.23%、4.26%、2.79%和2.39%；1年、3年、5年、10年和15年的RS率分别为15.47%、6.60%、4.69%、3.41%和3.29%。男性的这些OS率分别为14.95%、6.05%、4.06%、2.67%和2.26%，这些RS率分别为15.23%、6.41%、4.47%、3.26%和3.12%。女性的这些OS率分别为15.89%、6.79%、4.87%、3.17%和2.80%，这些RS率分别为16.20%、7.20%、5.37%、3.87%和3.82%。男女组之间未发现统计学差异（P>0.05）。15 - 34岁、35 - 44岁、45 - 54岁、55 - 64岁、65 - 74岁和75岁及以上年龄组的5年RS率分别为4.42%、4.29%、4.96%、4.67%、4.67%和6.35%，10年RS率分别为3.17%、2.98%、3.44%、3.47%、3.75%和11.27%。自20世纪80年代以来，该地区1年、3年、5年、10年和15年的OS率有显著改善。
启东登记的肝癌病例的生存结果在过去四十年中显示出逐步进展。早期检测和治疗的改善可能是肝癌预后改善的原因。虽然该地区与发达国家之间的生存差距正在缩小，但启东仍有必要提高生存率。
